Aktis Oncology (NASDAQ:AKTS) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Aktis Oncology (NASDAQ:AKTS) have received a consensus rating of “Moderate Buy” from the ten analysts that are currently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, eight have given a buy rating and one has given a strong buy rating to the company. The average 12-month target price among brokerages that have covered the stock in the last year is $35.00.

Several research analysts have weighed in on AKTS shares. JPMorgan Chase & Co. upped their price target on Aktis Oncology from $30.00 to $33.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 14th. Wedbush started coverage on shares of Aktis Oncology in a report on Wednesday, August 19th. They issued an “outperform” rating and a $35.00 target price on the stock. Weiss Ratings upgraded shares of Aktis Oncology from a “sell (d)” rating to a “sell (d+)” rating in a research report on Tuesday, June 23rd. Raymond James Financial initiated coverage on shares of Aktis Oncology in a research note on Monday, June 15th. They set a “strong-buy” rating and a $40.00 target price for the company. Finally, BMO Capital Markets initiated coverage on shares of Aktis Oncology in a report on Tuesday, August 18th. They set an “outperform” rating and a $37.00 price objective for the company.

Aktis Oncology Stock Performance

Shares of Aktis Oncology stock opened at $25.78 on Monday. Aktis Oncology has a fifty-two week low of $14.72 and a fifty-two week high of $34.19. The company has a market capitalization of $1.39 billion and a P/E ratio of -31.44. The company has a fifty day moving average of $25.81 and a 200 day moving average of $21.52.

Aktis Oncology (NASDAQ:AKTS) last announced its quarterly earnings data on Thursday, August 13th. The technology company reported ($0.44) EPS for the quarter, missing the consensus estimate of ($0.43) by ($0.01). The firm had revenue of $3.38 million during the quarter, compared to analyst estimates of $2.70 million. Analysts forecast that Aktis Oncology will post -1.8 EPS for the current year.

Insider Buying and Selling

In other Aktis Oncology news, Director Ken Herrmann sold 4,856 shares of the firm’s stock in a transaction that occurred on Monday, July 20th. The stock was sold at an average price of $24.56, for a total transaction of $119,263.36. Following the completion of the transaction, the director owned 3,506 shares in the company, valued at $86,107.36. This trade represents a 58.07% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. California State Teachers Retirement System purchased a new stake in Aktis Oncology during the second quarter valued at $288,000. Readystate Asset Management LP purchased a new position in shares of Aktis Oncology in the 2nd quarter worth $967,000. AXQ Capital LP purchased a new stake in shares of Aktis Oncology during the 2nd quarter valued at about $226,000. Susquehanna International Group LLP bought a new position in shares of Aktis Oncology in the 2nd quarter valued at about $278,000. Finally, Alyeska Investment Group L.P. purchased a new position in Aktis Oncology in the second quarter worth about $9,347,000. 28.84% of the stock is owned by hedge funds and other institutional investors.

Aktis Oncology Company Profile

Aktis Oncology (NASDAQ: AKTS) is a biotechnology company focused on the discovery and development of new therapies for cancer. The firm concentrates on advancing oncology candidates through research and development with the goal of addressing unmet medical needs in oncology. Its work emphasizes targeted and precision approaches intended to improve the safety and efficacy profiles of cancer treatments.

The company’s activities include laboratory research, preclinical studies and clinical development as it advances its pipeline programs toward regulatory milestones.